Clinical Research Directory
Browse clinical research sites, groups, and studies.
Specifying the Anti-inflammatory Effects of Ziltivekimab
Sponsor: Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
Summary
The goal of this randomized, double blind, placebo controlled trial is to study whether ziltivekimab therapy reduces arterial wall inflammation as assessed by imaging, and reduces the systemic inflammatory tone as assessed by circulating monocytes, inflammatory biomarkers and proteomics.
Official title: Specifying the Anti-inflammatory Effects of Ziltivekimab With Diverse Imaging Modalities and In-depth Cellular Phenotyping
Key Details
Gender
All
Age Range
50 Years - 85 Years
Study Type
INTERVENTIONAL
Enrollment
40
Start Date
2024-05-03
Completion Date
2026-10-01
Last Updated
2025-10-02
Healthy Volunteers
No
Conditions
Interventions
Ziltivekimab
Monoclonal antibody targeting IL-6
Placebo
Placebo
Locations (1)
Amsterdam UMC, location AMC
Amsterdam, Netherlands